Key result
In human resistance arteries, the combination of enalaprilat and chymostatin almost completely inhibited the contractile response to Ang I, whereas either inhibitor alone had no effect.
Human resistance arteries possess a dual pathway for Angiotensin II generation mediated by ACE and a chymostatin-sensitive enzyme (likely chymase), unlike rabbits where ACE is the sole pathway.
Answers are grounded in this paper and cite their sources.
Dual blockade may be required for full Ang II suppression in human vessels; leaves open chymase as a therapeutic target.
BACKGROUND: In vitro studies of myocardial tissue suggest that angiotensin II (Ang II) may be generated by both ACE and chymase. A similar dual pathway may exist in the vasculature. We studied the effects of ACE and chymase inhibitors on the contractile response to angiotensin I (Ang I) in human resistance arteries to investigate ACE-independent generation of Ang II. METHODS AND RESULTS: Subcutaneous resistance arteries (250 to 350 microm) were obtained from gluteal biopsies from volunteers and New Zealand White rabbits and mounted on a wire myograph. Contractile ability was tested with high-potassium depolarization and norepinephrine 10 micromol/L and endothelial integrity by relaxation to acetylcholine 3 micromol/L. Cumulative concentration-response curves were constructed for Ang I in the presence of enalaprilat 1 micromol/L, chymostatin 10 micromol/L, or both inhibitors together. In the rabbit, enalaprilat completely inhibited the Ang I response. In human vessels, enalaprilat or chymostatin alone had no effect, but the combination of enalaprilat and chymostatin almost completely inhibited the response to Ang I. CONCLUSIONS: A dual pathway for Ang II generation exists in human resistance arteries, mediated by ACE and a chymostatin-sensitive enzyme, probably chymase. We confirm that a marked species difference exists in the mechanism of Ang II generation between the human and the rabbit. More efficacious suppression of the renin-angiotensin system may require development of novel enzyme inhibitors or combinations of currently available drugs.
No takes yet. Share an insight, caveat, or question.
Padmanabhan et al. (1999) studied this question. Enalaprilat and chymostatin vs. Enalaprilat alone or chymostatin alone was evaluated on Contractile response to angiotensin I. In human resistance arteries, the combination of enalaprilat and chymostatin almost completely inhibited the contractile response to Ang I, whereas either inhibitor alone had no effect.
Synapse has enriched 10 related papers. Consider them for comparative context: